Related Experiment Videos
Fructosamine levels in CAPD: its value as glycemic index
F Coronel1, M Macia, A Cidoncha
1Hospital Universitario San Carlos, Madrid, Spain.
Summary
Fructosamine and glycosylated hemoglobin (HbA1c) effectively monitor blood glucose in diabetic patients on continuous ambulatory peritoneal dialysis (CAPD). These markers are reliable even with uremia or CAPD treatment.
Area of Science:
- Nephrology
- Endocrinology
- Clinical Chemistry
Background:
- Diabetes management in patients with chronic kidney disease (CKD) presents unique challenges.
- Glycemic control indicators like fructosamine and HbA1c require validation in CKD populations, particularly those on dialysis.
Purpose of the Study:
- To evaluate fructosamine and glycosylated hemoglobin (HbA1c) as glycemic indicators in uremic patients undergoing conservative management versus continuous ambulatory peritoneal dialysis (CAPD).
- To assess the influence of uremia and CAPD on these glycemic markers.
Main Methods:
- Compared fructosamine (colorimetric) and HbA1c (HPLC) levels in 20 conservatively managed uremic patients (8 diabetic, 12 non-diabetic) and 20 CAPD patients (12 diabetic, 8 non-diabetic) against 20 healthy controls.
- Correlated measurements with mean blood glucose (MBG) over preceding days.
Main Results:
- Non-diabetic uremic and CAPD patients showed no significant differences in fructosamine or HbA1c compared to controls.
- Diabetic patients on conservative treatment or CAPD exhibited elevated fructosamine and HbA1c levels, correlating with higher MBG.
- Strong correlations were found between fructosamine, HbA1c, and MBG in CAPD diabetic patients.
Conclusions:
- Fructosamine levels are not significantly affected by uremia or CAPD.
- Fructosamine and HPLC-measured HbA1c are reliable glycemic indicators for diabetic patients undergoing CAPD.